Journal of Commercial Biotechnology New Issue Published

Journal of Commercial Biotechnology

Labels, Lawyers, & Logic
Peter J. Pitts
America deserves access to high-quality health care without avoidable medical errors and complications. This achievable goal begins with harnessing and using the power of information. And that begins with clear, accurate, and usable labeling.The American health care system is undermined, underserved, and undervalued when labeling is written more for corporate liability protection than as a valuable tool for health care providers…
Full details at the Journal of Commercial Biotechnology

Improper Handling of Harmful Chemicals by Small Tea Growers of Assam: Challenge to Heath and Local Environment
Dhrubajyoti Gogoi, Abhishek Kumar Yadav, Madhurjya Gogoi, Debajit Borah
After dominating the world tea market since last 170 years, today India became the fourth largest tea exporter. The state Assam, located in the Northeastern end of the country contributes almost 50% of the India’s total tea production and Small tea growers of Assam (STGs) produces around 30% of its total annual production and contributes almost 12% of India’s annual production…
Full details at the Journal of Commercial Biotechnology

Trends in Market Access for Specialty Biologics: Challenges & Promises
Sanjay Kumar Rao
Specialty biologics are the fastest growing class of bio/pharmaceutical products in terms of the number of new brand launches and rates of health care spending in the U.S. and globally. Innovative biologics meant to treat a range of hitherto untreatable conditions in oncology, inflammation, CNS, endocrinology and other chronic conditions seek to offer radical improvements in efficacy and patient well-being…
Full details at the Journal of Commercial Biotechnology

Human Health Biotechnology: Can Brazil Advance?
Carlos Torres Freire, Victor Callil, Denise Golgher
The Brazilian human health biotechnology sector was analyzed according to its spacial and sectorial distribution of the following aspects: (i) the scientific production; (ii) dependence of companies on governmental funding for research and development; (iii) the lack of innovative capacity regarding the discovery and development of new drugs and (iv) a disconnection between the advancement of scientific output and innovation within the private sector…
Full details at the Journal of Commercial Biotechnology

Importance of venture capital investors for the industrial biotechnology industry
Gunter Festel, Christian Rammer
As in the medical biotechnology area some decades ago, the fast technological development within industrial biotechnology (IB) has caused numerous new ventures…
Full details at the Journal of Commercial Biotechnology

Early Commercial Assessments: An Innovative Tactic for Small Biotechs
Anthony Giovinazzo
As a small biotech company embarks on a drug development program, there is a tendency for management to focus on a well-defined set of issues. Is the science behind the drug valid? Does it solve an interesting problem or unmet need? What are the prospects that the medical community and patients will embrace it as a valuable new solution? And what is the range of indications the drug is conceived as addressing? These are all valid questions, but a small biotech can do even more to prepare itself for the drug development process, which is a journey that can take many years and cost a significant amount of money…
Full details at the Journal of Commercial Biotechnology

Accelerating the Growth of Bioeconomy in Malaysia
Nazlee Kamal, Zurina Che Dir
Advances in commercial application of biotechnology worldwide over the past two decades have led to the development of a bioeconomy, whereby substantial economic outputs are from the development and use of biological materials. Bioeconomy encompasses all industries and economic sectors based on the values implicit in biological materials that can be translated into new sources of income, environmental sustainability and social well-being…
Full details at the Journal of Commercial Biotechnology

Lean Start-up: A Comprehensive Case Study in the Establishment of Affordable Laboratory Infrastructure
Kristopher James Grohn, Kelsey Moody, Danique Wortel, Nick LeClair, Alison Traina, Eric Zluhan, Gerold Feuer
Historically, innovation in the biotechnology sector has relied to a large extent on the expensive infrastructure provided by universities or large pharmaceutical companies. This prohibitive start-up expense is the basis of why garage-style biotechnology entrepreneurs are exceedingly rare as compared to their software and high-tech counterparts…
Full details at the Journal of Commercial Biotechnology

The University of Colorado Certificate Program in Bioinnovation and Entrepreneurship: An Update and Current Status
Madhavan Parthasarathy, David Forlani, Arlen Meyers
The purpose of this paper is to provide an update and report the current status of the cross-campus University of Colorado Denver program in bioinnovation and entrepreneurship, details of which were first reported in the Journal of Commercial Biotechnology in 20125.  The paper outlines the joys and challenges of implementing an inter-campus program that attempts to marry cutting-edge biotechnology innovation with a solid business foundation…
Full details at the Journal of Commercial Biotechnology

Which Types of Bioinformatics Inventions Are Eligible for Patent Protection?
Trent Ostler, Michael Gollin
The field of bioinformatics is flourishing, and strong growth is only projected to continue. Like any cutting edge technology, bioinformatics requires an integrated IP strategy involving patent, trade secret, and copyright laws. The patent system in particular can be a powerful protection for commercializing bioinformatics inventions as long as a corresponding patent application meets certain patent law standards…
Full details at the Journal of Commercial Biotechnology

For more information, see the Journal of Commercial Biotechnology

Comments are closed.